Bruce Carter, Phd
Independent Director and Chairman of Nomination Co
Bruce Carter joined the IDRI Board of Directors in October 2014 and currently serves as chair. He began his career in drug discovery at G.D. Searle and later joined ZymoGenetics, Inc., where he served as president from 1988 to 1994 when Novo Nordisk acquired the company. At Novo Nordisk, Carter was Corporate Executive Vice President and Chief Scientific Officer until 2000 when he led a buyout of ZymoGenetics, establishing it as an independent company from Novo Nordisk.
He was named President and Chief Executive Officer and led ZymoGenetics' successful development and commercialization of Recothrom ®, a recombinant thrombin for use during surgical procedures. Bristol-Myers Squibb acquired ZymoGenetics in 2008. Most recently, Dr. Carter was Executive Chairman of Immune Design Corp. from 2009 to 2011.